` PSTV (Plus Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

PSTV
vs
S&P 500

Over the past 12 months, PSTV has underperformed S&P 500, delivering a return of -49% compared to the S&P 500's +14% growth.

Stocks Performance
PSTV vs S&P 500

Loading
PSTV
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PSTV vs S&P 500

Loading
PSTV
S&P 500
Difference
www.alphaspread.com

Performance By Year
PSTV vs S&P 500

Loading
PSTV
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Plus Therapeutics Inc vs Peers

S&P 500
PSTV
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Plus Therapeutics Inc
Glance View

Market Cap
72.2m USD
Industry
Biotechnology

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas and currently employs 14 full-time employees. The company went IPO on 2000-08-09. The firm is focused on developing treatments for patients battling cancer. The firm provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The firm is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The firm is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The firm also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.

PSTV Intrinsic Value
0.524 USD
Overvaluation 5%
Intrinsic Value
Price
Back to Top